U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Safety Considerations for Product Design to Minimize Medication Errors Guidance for Industry
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Safety Considerations for Product Design to Minimize Medication Errors Guidance for Industry April 2016

Download the Final Guidance Document Read the Federal Register Notice
Final
Docket Number:
FDA-2012-D-1005
Issued by:
Guidance Issuing Office
Center for Drug Evaluation and Research

The recommendations in this guidance apply broadly to the development of drug and biologic products. Accordingly, this guidance is intended for sponsors of investigational new drug applications (INDs); applicants of new drug applications (NDAs), biologics licensing applications (BLAs), abbreviated new drug applications (ANDAs);  and manufacturers of prescription drugs marketed without an approved application or over-the-counter (OTC) monograph drugs. This guidance provides a set of principles for using a systems approach to minimize medication errors relating to product design and container closure design and thus enhance patient safety.

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2012-D-1005.

Back to Top